Showing 35 results
  • infographic thumbnail
    PDF
    lock
    Fact Sheet
    Cardiovascular disease – ORION-8 media summary

    Long-term assessment of the efficacy and safety of inclisiran in patients with high risk of cardiovascular events

  • infographic thumbnail
    PDF
    lock
    Fact Sheet
    Cardiovascular disease – By the Numbers

    Cardiovascular disease (CVD) is the leading cause of death worldwide. Investment in heart health has declined for decades.

  • infographic thumbnail
    PDF
    lock
    Fact Sheet
    Cardiovascular disease – VictORION media summary

    A dynamic clinical trial program co-created with healthcare partners worldwide to generate evidence on the impact of cholesterol lowering with Leqvio® (Inclisiran).

  • Screenshot of title and primary endpoint of plain language media summary on SUNNY trials results
    PDF
    lock
    Fact Sheet
    52-week results for Cosentyx® in hidradenitis suppurativa: A summary

    Discover the data published in The Lancet on the long-term effect of Cosentyx® (secukinumab) in adults with hidradenitis suppurativa from the SUNRISE and SUNSHINE trials.

  • understanding-sma-backgrounder
    PDF
    lock
    Disease Awareness / Fact Sheet
    Spinal Muscular Atrophy

    Understanding spinal muscular atrophy, a rare, neuromuscular genetic disease.

  • the-novartis-aav-platform
    PDF
    lock
    Science & Innovation / Fact Sheet
    The Novartis AAV Platform

    Modified viruses – including adeno-associated viruses – are an efficient way to transport therapeutic genetic material to affected cells.

  • novartis-gene-therapies-manufacturing-fact-sheet
    PDF
    lock
    Science & Innovation / Fact Sheet
    The Novartis Gene Therapies Manufacturing Process

    Manufacturing of gene therapy is complex. Novartis has developed a reproducible manufacturing process.

  • novartis-gene-therapies-corporate-fact-sheet
    PDF
    lock
    Corporate Responsibility / Fact Sheet
    About Novartis Gene Therapies

    Novartis Gene Therapies is the world leader in gene therapy, and is reimagining medicine to transform the lives of patients.

  • gene-therapy-fact-sheet
    PDF
    lock
    Science & Innovation / Fact Sheet
    About Gene Therapy

    Gene therapy – an innovative approach to treating rare, genetic diseases.

  • PDF
    lock
    Products / Fact Sheet
    RTH258 Brolucizumab Clinical Trials

    Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.

  • PDF
    lock
    Products / Fact Sheet
    Kymriah® (tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice

    Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

  • PDF
    lock
    Products / Fact Sheet
    The JULIET Clinical Trial

    The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.